Investor Presentaiton
Clinical Development Portfolio - Phase III
OPDIVO
OPDIVO+YERVOY
OPDUALAG
✦ SC nivolumab + relatlimab + rHuPH20
✦ SC nivolumab + rHuPH20 (multi-indications)
+ ABECMA
iberdomide
mezigdomide
REBLOZYL
CAMZYOS
+ milvexian
✦ cendakimab
LPA1 Antagonist
✦ obexelimab * #
SOTYKTU
ZEPOSIA
ll, Bristol Myers Squibb Q3 2023 Results
Phase III
Adjuvant Hepatocellular Carcinoma
Peri-adjuvant Muscle-Invasive Urothelial Carcinoma
Peri-adjuvant Non-Small Cell Lung Cancer
Stage IB-IIIA Adjuvant NSCLC*
1L Hepatocellular Carcinoma
1L Muscle Invasive Urothelial Carcinoma
1L+ Microsatellite Instability High Colorectal Cancer
Stage 3 Unresectable Non-Small Cell Lung Cancer
Adjuvant Melanoma
2L/3L+ Metastatic Colorectal Cancer
1L Melanoma
2L Renal Cell Carcinoma
Newly Diagnosed Multiple Myeloma with Suboptimal
Response post-ASCT
+2L+ Multiple Myeloma
Post-Autologous Stem Cell Therapy Maintenance Newly
Diagnosed Multiple Myeloma
+2L+ Multiple Myeloma Vd
2L+ Multiple Myeloma Kd
1L TD Myelofibrosis Associated Anemia
1L NTD Myelodysplastic Syndrome Associated Anemia
Non-Obstructive Hypertrophic Cardiomyopathy
Secondary Stroke Prevention*
Acute Coronary Syndrome*
Atrial Fibrillation*
Eosinophilic Esophagitis
Eosinophilic Gastroenteritis #
Idiopathic Pulmonary Fibrosis (IPF)
Progressive Pulmonary Fibrosis (PPF)
IgG4-Related Disease
Psoriatic Arthritis
Systemic Lupus Erythematosus
Sjögren's Syndrome
Crohn's Disease
repotrectinib
ABECMA
REBLOZYL
*
Oncology
Data as of October 26th, 2023
Registration US, EU, JP
ROS1 NSCLC (US, JP)
3-5L Multiple Myeloma (US, EU, JP)
1L TD Myelodysplastic Syndrome Associated Anemia (EU, JP)
Hematology
CV
Neuroscience
Immunology
Partner-run study
✦ NME leading indication
# Certain Asian territories
Development Partnerships:
ABECMA: 2seventy bio; AHR: Ikena Oncology; Anti-MTBR-Tau: Prothena;
CAMZYOS in China, Singapore, Thailand, Macau, HK, Taiwan: LianBio;
farletuzumab ecteribulin: Eisai; rHuPH20: Halozyme; MAGEA4/8 TCER:
Immatics; milvexian: Janssen Pharmaceuticals, Inc.; OPDIVO, YERVOY,
OPDUALAG in Japan: Ono; PKCO Inhibitor: Exscientia; REBLOZYL: Merck; SHP2
Inhibitor: BridgeBio Pharma; TIGIT Bispecific: Agenus; obexelimab: Zenas
BioPharma in Japan, South Korea, Taiwan, HK, Singapore, and Australia
Not for Product Promotional Use
30View entire presentation